UNIverse - Public Research Portal
MALEavatar

Prof. Dr. med. Ludwig Kappos

Department of Clinical Research
Profiles & Affiliations

Publications

999 found
Show per page

Oh, J., Capezzuto, L., Kriara, L., Schjodt-Eriksen, J., van Beek, J., Bernasconi, C., Montalban, X., Butzkueven, H., Kappos, L., Giovannoni, G., Bove, R., Julian, L., Baker, M., Gossens, C., & Lindemann, M. (2024). Use of smartphone-based remote assessments of multiple sclerosis in Floodlight Open, a global, prospective, open-access study. Scientific Reports, 14(1). https://doi.org/10.1038/s41598-023-49299-4

URLs
URLs

Ciccarelli, O., Barkhof, F., Calabrese, M., De Stefano, N., Eshaghi, A., Filippi, M., Gasperini, C., Granziera, C., Kappos, L., Rocca, M. A., Rovira, À., Sastre-Garriga, J., Sormani, M. P., Tur, C., & Toosy, A. T. (2024). Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis [Journal-article]. Neurology, 103(1). https://doi.org/10.1212/wnl.0000000000209444

URLs
URLs

Chitnis, T., Banwell, B., Kappos, L., Arnold, D. L., Gücüyener, K., Deiva, K., Saubadu, S., Hu, W., Benamor, M., Le-Halpere, A., Truffinet, P., & Tardieu, M. (2024). Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS. Multiple Sclerosis Journal, 30(7), 833–842. https://doi.org/10.1177/13524585241242050

URLs
URLs

Fox, R. J., Cree, B. A. C., de Sèze, J., Gold, R., Hartung, H.-P., Jeffery, D., Kappos, L., Montalban, X., Weinstock-Guttman, B., Singh, C. M., Altincatal, A., Belviso, N., Avila, R. L., Ho, P.-R., Su, R., Engle, R., Sangurdekar, D., de Moor, C., Fisher, E., et al. (2024). Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis. Neurology, 102(9). https://doi.org/10.1212/wnl.0000000000209357

URLs
URLs

Woelfle, T., Hirt, J., Janiaud, P., Kappos, L., Ioannidis, J. P. A., & Hemkens, L. G. (2024). Benchmarking Human-AI Collaboration for Common Evidence Appraisal Tools [Posted-content]. Cold Spring Harbor Laboratory. https://doi.org/10.1101/2024.04.21.24306137

URLs
URLs

Weigel, M., Dechent, P., Galbusera, R., Bahn, E., Lu, P.-J., Kappos, L., Brück, W., Stadelmann, C., & Granziera, C. (2024). Cerebellar Ex Vivo Magnetic Resonance Imaging at its Feasibility Limit: Up to 77-Microns Isotropic Resolution using Low-Bandwidth Balanced Steady State Free Precession (LoBa-bSSFP) Sequences and 3T Standard Equipment [Posted-content]. Cold Spring Harbor Laboratory. https://doi.org/10.1101/2024.04.18.589707

URLs
URLs

Janiaud, Perrine, Zecca, Chiara, Salmen, Anke, Benkert, Pascal, Schädelin, Sabine, Orleth, Annette, Demuth, Lilian, Maceski, Aleksandra Maleska, Granziera, Cristina, Oechtering, Johanna, Leppert, David, Derfuss, Tobias, Achtnichts, Lutz, Findling, Oliver, Roth, Patrick, Lalive, Patrice, Uginet, Marjolaine, Müller, Stefanie, Pot, Caroline, et al. (2024). MultiSCRIPT-Cycle 1- A Pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in Multiple Sclerosis: a study protocol for a randomized clinical trial [Posted-content]. In medRxiv. Cold Spring Harbor Laboratory. https://doi.org/10.1101/2024.03.22.24304720

URLs
URLs

Cagol, Alessandro, Benkert, Pascal, Melie-Garcia, Lester, Schaedelin, Sabine A., Leber, Selina, Tsagkas, Charidimos, Barakovic, Muhamed, Galbusera, Riccardo, Lu, Po-Jui, Weigel, Matthias, Ruberte, Esther, Radue, Ernst-Wilhelm, Yaldizli, Özgür, Oechtering, Johanna, Lorscheider, Johannes, D’Souza, Marcus, Fischer-Barnicol, Bettina, Muller, Stefanie, Achtnichts, Lutz, et al. (2024). Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS. Neurology, 102. https://doi.org/10.1212/wnl.0000000000207768

URLs
URLs

Derfuss, T., Bermel, R., Lin, C.-J., Hauser, S. L., Kappos, L., Vollmer, T., Comi, G., Giovannoni, G., Hartung, H.-P., Weber, M. S., Wang, J., Jessop, N., Chognot, C., Craveiro, L., & Bar-Or, A. (2024). Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials [Journal-article]. Therapeutic Advances in Neurological Disorders, 17. https://doi.org/10.1177/17562864241277736

URLs
URLs

Galbusera, Riccardo, Bahn, Erik, Weigel, Matthias, Cagol, Alessandro, Lu, Po-Jui, Schaedelin, Sabine A., Franz, Jonas, Barakovic, Muhamed, Rahmanzadeh, Reza, Dechent, Peter, Nair, Govind, Brück, Wolfgang, Kuhle, Jens, Kappos, Ludwig, Stadelmann, Christine, & Granziera, Cristina. (2024). Characteristics, Prevalence, and Clinical Relevance of Juxtacortical Paramagnetic Rims in Patients With Multiple Sclerosis. Neurology, 102, e207966. https://doi.org/10.1212/wnl.0000000000207966

URLs
URLs

Gloor M, Andelova M, Gaetano L, Papadopoulou A, Burguet Villena F, Sprenger T, Radue EW, Kappos L, Bieri O, & Garcia M. (2024). Longitudinal analysis of new multiple sclerosis lesions with magnetization transfer and diffusion tensor imaging. European Society of Radiology. https://doi.org/10.1007/s00330-023-10173-6

Greselin, Martina, Lu, Po-Jui, Melie-Garcia, Lester, Ocampo-Pineda, Mario, Galbusera, Riccardo, Cagol, Alessandro, Weigel, Matthias, de Oliveira Siebenborn, Nina, Ruberte, Esther, Benkert, Pascal, Müller, Stefanie, Finkener, Sebastian, Vehoff, Jochen, Disanto, Giulio, Findling, Oliver, Chan, Andrew, Salmen, Anke, Pot, Caroline, Bridel, Claire, et al. (2024). Contrast-Enhancing Lesion Segmentation in Multiple Sclerosis: A Deep Learning Approach Validated in a Multicentric Cohort [Journal-article]. Bioengineering, 11(8), 858. https://doi.org/10.3390/bioengineering11080858

URLs
URLs

Hirt, Julian, Dembowska, Kinga, Woelfle, Tim, Axfors, Cathrine, Granziera, Cristina, Kuhle, Jens, Kappos, Ludwig, Hemkens, Lars G., & Janiaud, Perrine. (2024). Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis. Journal of Neurology. https://doi.org/10.1007/s00415-024-12366-5

URLs
URLs

Hirt, Julian, Janiaud, Perrine, Düblin, Pascal, Nicoletti, Giovanni Jacopo, Dembowska, Kinga, Nguyen, Thao Vy Thi, Woelfle, Tim, Axfors, Cathrine, Yaldizli, Özgür, Granziera, Cristina, Kuhle, Jens, Kappos, Ludwig, & Hemkens, Lars G. (2024). Use of pragmatic randomized trials in multiple sclerosis: A systematic overview. Multiple Sclerosis Journal, 30, 463–478. https://doi.org/10.1177/13524585231221938

URLs
URLs

Janiaud, Perrine, Zecca, Chiara, Salmen, Anke, Benkert, Pascal, Schädelin, Sabine, Orleth, Annette, Demuth, Lilian, Maceski, Aleksandra Maleska, Granziera, Cristina, Oechtering, Johanna, Leppert, David, Derfuss, Tobias, Achtnichts, Lutz, Findling, Oliver, Roth, Patrick, Lalive, Patrice, Uginet, Marjolaine, Müller, Stefanie, Pot, Caroline, et al. (2024). MultiSCRIPT-Cycle 1—a pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: a study protocol for a randomized clinical trial. Trials, 25. https://doi.org/10.1186/s13063-024-08454-6

URLs
URLs

Kappos, L., Edan, G., Freedman, M. S., Hartung, H.-P., Montalbán, X., Barkhof, F., Koelbach, R., MacManus, D. G., & Wicklein, E.-M. (2024). Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial. Journal of Neurology. https://doi.org/10.1007/s00415-024-12417-x

URLs
URLs

Kappos, Ludwig, Traboulsee, Anthony, Li, David K. B., Bar-Or, Amit, Barkhof, Frederik, Montalban, Xavier, Leppert, David, Baldinotti, Anna, Schneble, Hans-Martin, Koendgen, Harold, Sauter, Annette, Wang, Qing, & Hauser, Stephen L. (2024). Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension. Journal of Neurology, 271, 642–657. https://doi.org/10.1007/s00415-023-11943-4

URLs
URLs

Müller, Jannis, Lu, Po-Jui, Cagol, Alessandro, Ruberte, Esther, Shin, Hyeong-Geol, Ocampo-Pineda, Mario, Chen, Xinjie, Tsagkas, Charidimos, Barakovic, Muhamed, Galbusera, Riccardo, Weigel, Matthias, Schaedelin, Sabine A., Wang, Yi, Nguyen, Thanh D., Spincemaille, Pascal, Kappos, Ludwig, Kuhle, Jens, Lee, Jongho, & Granziera, Cristina. (2024). Quantifying Remyelination Using χ-Separation in White Matter and Cortical Multiple Sclerosis Lesions [Journal-article]. Neurology, 103(6). https://doi.org/10.1212/WNL.0000000000209604

URLs
URLs

Hauser S.L., Kappos L., Bar-Or A., Wiendl H., Paling D., Williams M., Gold R., Chan A., Milo R., Das Gupta A., Karlsson G., Sullivan R., Graham G., Merschhemke M., Haring D.A., & Vermersch P. (2023). The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment. Neurology and Therapy, 12(5), 1491–1515. https://doi.org/10.1007/s40120-023-00518-0

URLs
URLs

Hauser, S. L., Zielman, R., Das Gupta, A., Xi, J., Stoneman, D., Karlsson, G., Robertson, D., Cohen, J. A., & Kappos, L. (2023). Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension. Multiple Sclerosis Journal, 29(11-12), 1452–1464. https://doi.org/10.1177/13524585231195346

URLs
URLs

Woelfle T, Bourguignon L, Lorscheider J, Kappos L, Naegelin Y, & Jutzeler CR. (2023). Wearable Sensor Technologies to Assess Motor Functions in People With Multiple Sclerosis: Systematic Scoping Review and Perspective. Journal of Medical Internet Research, 25, e44428. https://doi.org/10.2196/44428

URLs
URLs

Diouf I, Malpas CB, Sharmin S, Roos I, Horakova D, Kubala Havrdova E, Patti F, Shaygannejad V, Ozakbas S, Eichau S, Onofrj M, Lugaresi A, Alroughani R, Prat A, Duquette P, Terzi M, Boz C, Grand’Maison F, Sola P, et al. (2023). Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial. Journal of Neurology, Neurosurgery, and Psychiatry. https://doi.org/10.1136/jnnp-2023-331499

URLs
URLs

Pless S, Woelfle T, Naegelin Y, Lorscheider J, Wiencierz A, Reyes Ó, Calabrese P, & Kappos L. (2023). Assessment of cognitive performance in multiple sclerosis using smartphone-based training games: a feasibility study. Journal of Neurology, 270(7), 3451–3463. https://doi.org/10.1007/s00415-023-11671-9

URLs
URLs

Cortese R., Battaglini M., Prados F., Bianchi A., Haider L., Jacob A., Palace J, Messina S., Paul F, Wuerfel J., Marignier R., Durand-Dubief F., de Medeiros Rimkus C., Callegaro D., Sato D.K., Filippi M, Rocca MA, Cacciaguerra L., Rovira A, et al. (2023). Clinical and MRI measures to identify non-acute MOG-antibody disease in adults. Brain, 146(6), 2489–2501. https://doi.org/10.1093/brain/awac480

URLs
URLs

Pfeuffer S., Rolfes L., Ingwersen J., Pul R., Kleinschnitz K., Korsen M., Rauber S., Ruck T., Schieferdecker S., Willison A.G., Aktas O., Kleinschnitz C., Hartung H.-P., Kappos L., & Meuth S.G. (2023). Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab. Neurology(R) Neuroimmunology & Neuroinflammation, 10(3). https://doi.org/10.1212/nxi.0000000000200104

URLs
URLs

Cagol A., Fuertes N.C., Stoessel M., Barakovic M., Schaedelin S., D’Souza M, Wurfel J., Brandt A.U., Kappos L., Sprenger T, Naegelin Y, Kuhle J, Granziera C, & Papadopoulou A. (2023). Optical coherence tomography reflects clinically relevant gray matter damage in patients with multiple sclerosis. Journal of Neurology, 270(4), 2139–2148. https://doi.org/10.1007/s00415-022-11535-8

URLs
URLs

Diouf I., Malpas C.B., Sharmin S., Roos I., Horakova D., Havrdova E.K., Patti F., Shaygannejad V., Ozakbas S., Izquierdo G., Eichau S., Onofrj M., Lugaresi A., Alroughani R., Prat A., Girard M., Duquette P., Terzi M., Boz C., et al. (2023). Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis. European Journal of Neurology, 30(4), 1014–1024. https://doi.org/10.1111/ene.15706

URLs
URLs

Vrenken H., Battaglini M., de Vos M.L., Nagtegaal G.J., Teixeira B.C.A., Seitzinger A., Jack D., Sormani M.P., Uitdehaag B.M.J., Versteeg A., Comi G., Kappos L., De Stefano N., & Barkhof F. (2023). Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a. Journal of Neurology, 270(4), 2271–2282. https://doi.org/10.1007/s00415-022-11554-5

URLs
URLs

Hauser S.L., Bar-Or A., Weber M.S., Kletzl H., Gunther A., Manfrini M., Model F., Mercier F., Petry C., Wing Q., Koendgen H., Smith T., & Kappos L. (2023). Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 10(2). https://doi.org/10.1212/nxi.0000000000200094

URLs
URLs

Kuhle J, Chitnis T., Banwell B., Tardieu M., Arnold DL, Rawlings A.M., Geertsen S.S., Lublin AL, Saubadu S., Truffinet P., & Kappos L. (2023). Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial. Multiple Sclerosis Journal, 29(3), 385–394. https://doi.org/10.1177/13524585221144742

URLs
URLs

Tsagkas, Charidimos, Huck-Horvath, Antal, Cagol, Alessandro, Haas, Tanja, Amann, Michael, Barakovic, Muhamed, Ruberte, Esther, Melie-Garcia, Lester, Weigel, Matthias, Pezold, Simon, Schlaeger, Regina, Kuhle, Jens, Sprenger, Till, Kappos, Ludwig, Bieri, Oliver, Cattin, Philippe, Granziera, Cristina, & Parmar, Katrin. (2023). Longitudinal assessment of cervical spinal cord compartments in multiple sclerosis [Journal-article]. Multiple Sclerosis and Related Disorders, 71, 104545. https://doi.org/10.1016/j.msard.2023.104545

Tsagkas C, Huck-Horvath A, Cagol A, Haas T, Amann M, Barakovic M, Ruberte E, Melie-Garcia L, Weigel M, Pezold S, Schlaeger R, Kuhle J, Sprenger T, Kappos L, Bieri O, Cattin P, Granziera C, & Parmar K. (2023). Longitudinal assessment of cervical spinal cord compartments in multiple sclerosis. Multiple Sclerosis and Related Disorders, 71, 104545. https://doi.org/10.1016/j.msard.2023.104545

URLs
URLs

Tsagkas C, Horvath-Huck A, Haas T, Amann M, Todea A, Altermatt A, Müller J, Cagol A, Leimbacher M, Barakovic M, Weigel M, Pezold S, Sprenger T, Kappos L, Bieri O, Granziera C, Cattin P, & Parmar K. (2023). Fully Automatic Method for Reliable Spinal Cord Compartment Segmentation in Multiple Sclerosis. AJNR. American Journal of Neuroradiology, 44(2), 218–227. https://doi.org/10.3174/ajnr.a7756

URLs
URLs

Ziemssen T., Bhan V., Chataway J., Chitnis T., Campbell Cree B.A., Havrdova E.K., Kappos L., Labauge P., Miller A., Nakahara J., Oreja-Guevara C., Palace J., Singer B., Trojano M., Patil A., Rauser B., & Hach T. (2023). Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies. Neurology: Neuroimmunology and NeuroInflammation, 10(1). https://doi.org/10.1212/nxi.0000000000200064

URLs
URLs

Abdelhak, Ahmed, Benkert, Pascal, Schaedelin, Sabine, Boscardin, W. John, Cordano, Christian, Oechtering, Johanna, Ananth, Kirtana, Granziera, Cristina, Melie-Garcia, Lester, Montes, Shivany Condor, Beaudry-Richard, Alexandra, Achtnichts, Lutz, Oertel, Frederike C., Lalive, Patrice H., Leppert, David, Müller, Stefanie, Henry, Roland G., Pot, Caroline, Matthias, Amandine, et al. (2023). Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis. JAMA Neurology, 80, 1317–1325. https://doi.org/10.1001/jamaneurol.2023.3997

URLs
URLs

Abdelhak, Ahmed, Petermeier, Franziska, Benkert, Pascal, Schädelin, Sabine, Oechtering, Johanna, Maleska Maceski, Aleksandra, Kabesch, Michael, Geis, Tobias, Laub, Otto, Leipold, Georg, Gobbi, Claudio, Zecca, Chiara, Green, Ari, Tumani, Hayrettin, Willemse, Eline, Wiendl, Heinz, Granziera, Cristina, Kappos, Ludwig, Leppert, David, et al. (2023). Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study. The Lancet Neurology, 22, 826–833. https://doi.org/10.1016/s1474-4422(23)00210-7

URLs
URLs

Ayroza Galvão Ribeiro Gomes, Ana Beatriz, Kulsvehagen, Laila, Lipps, Patrick, Cagol, Alessandro, Cerdá-Fuertes, Nuria, Neziraj, Tradite, Flammer, Julia, Lerner, Jasmine, Lecourt, Anne-Catherine, De Oliveira S. Siebenborn, Nina, Cortese, Rosa, Schaedelin, Sabine, Andreoli Schoeps, Vinicius, De Moura Brasil Matos, Aline, Trombini Mendes, Natalia, Dos Reis Pereira, Clarissa, Ribeiro Monteiro, Mario Luiz, Dos Apóstolos-Pereira, Samira Luisa, Schindler, Patrick, et al. (2023). Immunoglobulin A Antibodies Against Myelin Oligodendrocyte Glycoprotein in a Subgroup of Patients with Central Nervous System Demyelination. JAMA Neurology, 80, 989–995. https://doi.org/10.1001/jamaneurol.2023.2523

URLs
URLs

Bar-Or, Amit, Thanei, Gian-Andrea, Harp, Christopher, Bernasconi, Corrado, Bonati, Ulrike, Cross, Anne H., Fischer, Saloumeh, Gaetano, Laura, Hauser, Stephen L., Hendricks, Robert, Kappos, Ludwig, Kuhle, Jens, Leppert, David, Model, Fabian, Sauter, Annette, Koendgen, Harold, Jia, Xiaoming, & Herman, Ann E. (2023). Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials. eBioMedicine, 93. https://doi.org/10.1016/j.ebiom.2023.104662

URLs
URLs

Bühler A, Wolbers M, Model F, Wang Q, Belachew S, Manfrini M, Lorscheider J, Kappos L, & Beyersmann J. (2023). Recurrent disability progression endpoints in multiple sclerosis clinical trials. Multiple Sclerosis (Houndmills, Basingstoke, England), 29(1), 130–139. https://doi.org/10.1177/13524585221125382

URLs
URLs

Callegari, Ilaria, Schneider, Mika, Aebischer, Vera, Voortman, Margarete M., Proschmann, Undine, Ziemssen, Tjalf, Lindberg, Raija, Fischer-Barnicol, Bettina, Khalil, Michael, Kappos, Ludwig, Kuhle, Jens, Sanderson, Nicholas S.R., & Derfuss, Tobias. (2023). Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis. Therapeutic Advances in Neurological Disorders, 16. https://doi.org/10.1177/17562864221150040

URLs
URLs

Cerdá-Fuertes, Nuria, Nagy, Sara, Schaedelin, Sabine, Sinnecker, Tim, Ruberte, Esther, Papadopoulou, Athina, Würfel, Jens, Kuhle, Jens, Yaldizli, Özgür, Kappos, Ludwig, Derfuss, Tobias, & Décard, Bernhard F. (2023). Evaluation of frequency, severity, and independent risk factors for recurrence of disease activity after fingolimod discontinuation in a large real-world cohort of patients with multiple sclerosis. Therapeutic Advances in Neurological Disorders, 16. https://doi.org/10.1177/17562864221150312

URLs
URLs

Cerdá-Fuertes, Nuria, Stoessel, Marc, Mickeliunas, Gintaras, Pless, Silvan, Cagol, Alessandro, Barakovic, Muhamed, Maceski, Aleksandra Maleska, Álvarez González, Cesar, D’ Souza, Marcus, Schaedlin, Sabine, Benkert, Pascal, Calabrese, Pasquale, Gugleta, Konstantin, Derfuss, Tobias, Sprenger, Till, Granziera, Cristina, Naegelin, Yvonne, Kappos, Ludwig, Kappos, Ludwig, et al. (2023). Optical coherence tomography versus other biomarkers: Associations with physical and cognitive disability in multiple sclerosis. Multiple Sclerosis Journal, 29, 1540–1550. https://doi.org/10.1177/13524585231198760

URLs
URLs

Chen, Xinjie, Schädelin, Sabine, Lu, Po-Jui, Ocampo-Pineda, Mario, Weigel, Matthias, Barakovic, Muhamed, Ruberte, Esther, Cagol, Alessandro, Marechal, Benedicte, Kober, Tobias, Kuhle, Jens, Kappos, Ludwig, Melie-Garcia, Lester, & Granziera, Cristina. (2023). Personalized maps of T1 relaxometry abnormalities provide correlates of disability in multiple sclerosis patients. NeuroImage: Clinical, 37. https://doi.org/10.1016/j.nicl.2023.103349

URLs
URLs

Galbusera, Riccardo, Bahn, Erik, Weigel, Matthias, Schaedelin, Sabine, Franz, Jonas, Lu, Po-Jui, Barakovic, Muhamed, Melie-Garcia, Lester, Dechent, Peter, Lutti, Antoine, Sati, Pascal, Reich, Daniel S., Nair, Govind, Brück, Wolfgang, Kappos, Ludwig, Stadelmann, Christine, & Granziera, Cristina. (2023). Postmortem quantitative MRI disentangles histological lesion types in multiple sclerosis. Brain Pathology, 33. https://doi.org/10.1111/bpa.13136

URLs
URLs

Gentile G., Mattiesing R.M., Brouwer I., van Schijndel R.A., Uitdehaag B.M.J., Twisk J.W.R., Kappos L., Freedman M.S., Comi G., Jack D., Barkhof F., De Stefano N., Vrenken H., & Battaglini M. (2023). The spatio-temporal relationship between concurrent lesion and brain atrophy changes in early multiple sclerosis: A post-hoc analysis of the REFLEXION study. NeuroImage: Clinical, 38. https://doi.org/10.1016/j.nicl.2023.103397

URLs
URLs

Granziera, Cristina, Derfuss, Tobias, & Kappos, Ludwig. (2023). Time to Change the Current Clinical Classification of Multiple Sclerosis? JAMA Neurology, 80, 128–130. https://doi.org/10.1001/jamaneurol.2022.4156

URLs
URLs

Harding-Forrester, Sam, Roos, Izanne, Nguyen, Ai-Lan, Malpas, Charles B, Diouf, Ibrahima, Moradi, Nahid, Sharmin, Sifat, Izquierdo, Guillermo, Eichau, Sara, Patti, Francesco, Horakova, Dana, Kubala Havrdova, Eva, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grand’Maison, Francois, Onofrj, Marco, Lugaresi, Alessandra, Grammond, Pierre, et al. (2023). Disability accrual in primary and secondary progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 94, 707–717. https://doi.org/10.1136/jnnp-2022-330726

URLs
URLs

Kappos L., Barkhof F., & Uitdehaag B. (2023). Otto van Eikema Hommes – 7 February 1932 – 16 August 2022. Multiple Sclerosis Journal, 29(1), 6–7. https://doi.org/10.1177/13524585221139153

URLs
URLs

Meier, Stephanie, Willemse, Eline A.J., Schaedelin, Sabine, Oechtering, Johanna, Lorscheider, Johannes, Melie-Garcia, Lester, Cagol, Alessandro, Barakovic, Muhamed, Galbusera, Riccardo, Subramaniam, Suvitha, Barro, Christian, Abdelhak, Ahmed, Thebault, Simon, Achtnichts, Lutz, Lalive, Patrice, Müller, Stefanie, Pot, Caroline, Salmen, Anke, Disanto, Giulio, et al. (2023). Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis. JAMA Neurology, 80, 287–297. https://doi.org/10.1001/jamaneurol.2022.5250

URLs
URLs

Müller, Jannis, Cagol, Alessandro, Lorscheider, Johannes, Tsagkas, Charidimos, Benkert, Pascal, Yaldizli, Özgür, Kuhle, Jens, Derfuss, Tobias, Sormani, Maria Pia, Thompson, Alan, Granziera, Cristina, & Kappos, Ludwig. (2023). Harmonizing Definitions for Progression Independent of Relapse Activity inMultiple Sclerosis A Systematic Review. JAMA Neurology, 80, 1232–1245. https://doi.org/10.1001/jamaneurol.2023.3331

URLs
URLs

Neziraj, Tradite, Kappos, Ludwig, & Pröbstel, Anne-Katrin. (2023). Moving toward personalized B cell depletion in multiple sclerosis? Med, 4(6), 344–346. https://doi.org/10.1016/j.medj.2023.05.006

URLs
URLs

Todea, Alexandra Ramona, Melie-Garcia, Lester, Barakovic, Muhamed, Cagol, Alessandro, Rahmanzadeh, Reza, Galbusera, Riccardo, Lu, Po-Jui, Weigel, Matthias, Ruberte, Esther, Radue, Ernst-Wilhelm, Schaedelin, Sabine, Benkert, Pascal, Oezguer, Yaldizli, Sinnecker, Tim, Müller, Stefanie, Achtnichts, Lutz, Vehoff, Jochen, Disanto, Giulio, Findling, Oliver, et al. (2023). A Multicenter Longitudinal MRI Study Assessing LeMan-PV Software Accuracy in the Detection of White Matter Lesions in Multiple Sclerosis Patients. Journal of Magnetic Resonance Imaging, 58, 864–876. https://doi.org/10.1002/jmri.28618

URLs
URLs

Tsagkas, Charidimos, Huck-Horvath, Antal, Cagol, Alessandro, Haas, Tanja, Barakovic, Muhamed, Amann, Michael, Ruberte, Esther, Melie-Garcia, Lester, Weigel, Matthias, Pezold, Simon, Schlaeger, Regina, Kuhle, Jens, Sprenger, Till, Kappos, Ludwig, Bieri, Oliver, Cattin, Philippe, Granziera, Cristina, & Parmar, Katrin. (2023). Anterior horn atrophy in the cervical spinal cord: A new biomarker in progressive multiple sclerosis. Multiple Sclerosis Journal, 29, 702–718. https://doi.org/10.1177/13524585221139152

URLs
URLs

van Munster, Caspar E.P., Burggraaff, Jessica, Steinheimer, Saskia, Kamm, Christian P., D’Souza, Marcus, Diederich, Manuela, Dorn, Jonas, Walsh, Lorcan, Dahlke, Frank, Kappos, Ludwig, & Uitdehaag, Bernard M.J. (2023). Assessment of Multiple Aspects of Upper Extremity Function Independent From Ambulation in Patients With Multiple Sclerosis. International Journal of MS Care, 25, 226–232. https://doi.org/10.7224/1537-2073.2021-069

URLs
URLs

Wenger A.L., Barakovic, Muhamed, Bosticardo, Sara, Schaedelin, Sabine, Daducci, Alessandro, Schiavi, Simona, Weigel, Matthias, Rahmanzadeh, Reza, Lu, Po-Jui, Cagol, Alessandro, Kappos, Ludwig, Kuhle, Jens, Calabrese, Pasquale, & Granziera, Cristina. (2023). An investigation of the association between focal damage and global network properties in cognitively impaired and cognitively preserved patients with multiple sclerosis. Frontiers in Neuroscience, 17. https://doi.org/10.3389/fnins.2023.1007580

URLs
URLs

Wilson, David, Chan, Dandan, Chang, Lei, Mathis, Robert, Verberk, Inge, Montalban, Xavier, Comabella, Manuel, Fissolo, Nicolas, Bielekova, Bibi, Masvekar, Ruturaj, Chitnis, Tanuja, Ziemssen, Tjalf, Akgün, Katja, Blennow, Kaj, Zetterberg, Henrik, Brück, Wolfgang, Giovannoni, Gavin, Gnanapavan, Sharmilee, Bittner, Stefan, et al. (2023). Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: Toward a clinical blood test for neuronal injury. Clinical Chemistry and Laboratory Medicine, null. https://doi.org/10.1515/cclm-2023-0518

URLs
URLs

Woelfle, Tim, Pless, Silvan, Reyes, Óscar, Wiencierz, Andrea, Kappos, Ludwig, Granziera, Cristina, & Lorscheider, Johannes. (2023). Smartwatch-derived sleep and heart rate measures complement step counts in explaining established metrics of MS severity. Multiple Sclerosis and Related Disorders, 80. https://doi.org/10.1016/j.msard.2023.105104

URLs
URLs

Woelfle T, Pless S, Reyes O, Wiencierz A, Feinstein A, Calabrese P, Gugleta K, Kappos L, Lorscheider J, & Naegelin Y. (2023). Reliability and acceptance of dreaMS, a software application for people with multiple sclerosis: a feasibility study. Journal of Neurology, 270(1), 262–271. https://doi.org/10.1007/s00415-022-11306-5

URLs
URLs

Chang I, Kappos L, Giovannoni G, Calabresi PA, Sandrock A, Cheng W, Xiao S, Riester K, Belachew S, Deykin A, & Zhu B. (2022). Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England), 28(14), 2263–2273. https://doi.org/10.1177/13524585221114997

URLs
URLs

Meaton I, Altokhis A, Allen CM, Clarke MA, Sinnecker T, Meier D, Enzinger C, Calabrese M, De Stefano N, Pitiot A, Giorgio A, Schoonheim MM, Paul F, Pawlak MA, Schmidt R, Granziera C, Kappos L, Montalban X, Rovira À, et al. (2022). Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England), 28(14), 2212–2220. https://doi.org/10.1177/13524585221118677

URLs
URLs

Woelfle, T., Bourguignon, L., Lorscheider, J., Kappos, L., Naegelin, Y., & Jutzeler, C. R. (2022, November 18). Wearable Sensor Technologies to Assess Motor Functions in People With Multiple Sclerosis: Systematic Scoping Review and Perspective (Preprint) [Posted-content]. JMIR Publications Inc. https://doi.org/10.2196/preprints.44428

URLs
URLs

Roos I, Malpas C, Leray E, Casey R, Horakova D, Havrdova EK, Debouverie M, Patti F, De Seze J, Izquierdo G, Eichau S, Edan G, Prat A, Girard M, Ozakbas S, Grammond P, Zephir H, Ciron J, Maillart E, et al. (2022). Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis. Neurology, 99(17), e1926–e1944. https://doi.org/10.1212/wnl.0000000000201029

URLs
URLs

Leppert D, Kropshofer H, Häring D, Dahlke F, Patil A, Meinert R, Tomic D, Kappos L, & Kuhle J. (2022). Author Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials. Neurology, 99(14), 631. https://doi.org/10.1212/wnl.0000000000201277

URLs
URLs

Arnold, Douglas L, Sprenger, Till, Bar-Or, Amit, Wolinsky, Jerry S, Kappos, Ludwig, Kolind, Shannon, Bonati, Ulrike, Magon, Stefano, van Beek, Johan, Koendgen, Harold, Bortolami, Oscar, Bernasconi, Corrado, Gaetano, Laura, & Traboulsee, Anthony. (2022). Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS [Journal-article]. Multiple Sclerosis Journal, 28(12), 1927–1936. https://doi.org/10.1177/13524585221097561

URLs
URLs

Cree BA, Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, Hartung HP, Montalbán X, Havrdová EK, Sheffield JK, Minton N, Cheng CY, Silva D, Kappos L, & Cohen JA. (2022). Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial. Multiple Sclerosis (Houndmills, Basingstoke, England), 28(12), 1944–1962. https://doi.org/10.1177/13524585221102584

URLs
URLs

Kalincik T, Kister I, Bacon TE, Malpas CB, Sharmin S, Horakova D, Kubala-Havrdova E, Patti F, Izquierdo G, Eichau S, Ozakbas S, Onofrj M, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Sola P, Ferraro D, et al. (2022). Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. Multiple Sclerosis (Houndmills, Basingstoke, England), 28(11), 1752–1761. https://doi.org/10.1177/13524585221084577

URLs
URLs

Sprenger T, Kappos L, Sormani MP, Miller AE, Poole EM, Cavalier S, & Wuerfel J. (2022). Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies. Multiple Sclerosis (Houndmills, Basingstoke, England), 28(11), 1719–1728. https://doi.org/10.1177/13524585221089534

URLs
URLs

Arnold DL, Piani-Meier D, Bar-Or A, Benedict RH, Cree BA, Giovannoni G, Gold R, Vermersch P, Arnould S, Dahlke F, Hach T, Ritter S, Karlsson G, Kappos L, Fox RJ, & EXPAND Clinical Investigators. (2022). Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial. Multiple Sclerosis (Houndmills, Basingstoke, England), 28(10), 1526–1540. https://doi.org/10.1177/13524585221076717

URLs
URLs

Cree BA, Arnold DL, Fox RJ, Gold R, Vermersch P, Benedict RH, Bar-Or A, Piani-Meier D, Rouyrre N, Ritter S, Kilaru A, Karlsson G, Giovannoni G, & Kappos L. (2022). Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years. Multiple Sclerosis (Houndmills, Basingstoke, England), 28(10), 1591–1605. https://doi.org/10.1177/13524585221083194

URLs
URLs

Gärtner J, Hauser SL, Bar-Or A, Montalban X, Cohen JA, Cross AH, Deiva K, Ganjgahi H, Häring DA, Li B, Pingili R, Ramanathan K, Su W, Willi R, Kieseier B, & Kappos L. (2022). Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II. Multiple Sclerosis (Houndmills, Basingstoke, England), 28(10), 1562–1575. https://doi.org/10.1177/13524585221078825

URLs
URLs

Gold R, Piani-Meier D, Kappos L, Bar-Or A, Vermersch P, Giovannoni G, Fox RJ, Arnold DL, Benedict RHB, Penner IK, Rouyrre N, Kilaru A, Karlsson G, Ritter S, Dahlke F, Hach T, & Cree BAC. (2022). Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study. Journal of Neurology, 269(9), 5093–5104. https://doi.org/10.1007/s00415-022-11166-z

URLs
URLs

Hauser SL, Cross AH, Winthrop K, Wiendl H, Nicholas J, Meuth SG, Giacomini PS, Saccà F, Mancione L, Zielman R, Bagger M, Das Gupta A, Häring DA, Jehl V, Kieseier BC, Pingili R, Stoneman D, Su W, Willi R, & Kappos L. (2022). Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years. Multiple Sclerosis (Houndmills, Basingstoke, England), 28(10), 1576–1590. https://doi.org/10.1177/13524585221079731

URLs
URLs

Lam KH, van Munster CEP, D’Souza M, Steinheimer S, Kamm CP, Burggraaff J, Johnson M, Zaykov Y, Dorn J, Dahlke F, Kappos L, Killestein J, & Uitdehaag B. (2022). Improving Detection of Change in Motor Functioning in Multiple Sclerosis Using Video-Assisted Composite Measures. International Journal of MS Care, 24(5), 230–234. https://doi.org/10.7224/1537-2073.2021-044

URLs
URLs

Rahmanzadeh R, Galbusera R, Lu PJ, Bahn E, Weigel M, Barakovic M, Franz J, Nguyen TD, Spincemaille P, Schiavi S, Daducci A, La Rosa F, Absinta M, Sati P, Bach Cuadra M, Radue EW, Leppert D, Kuhle J, Kappos L, et al. (2022). A New Advanced MRI Biomarker for Remyelinated Lesions in Multiple Sclerosis. Annals of Neurology, 92(3), 486–502. https://doi.org/10.1002/ana.26441

URLs
URLs

Granziera C, Woelfle T, & Kappos L. (2022). Development and implementation of new diagnostic technologies in neurology. Nature Reviews. Neurology, 18(8), 445–446. https://doi.org/10.1038/s41582-022-00692-z

URLs
URLs

Parmar K, Fonov VS, Naegelin Y, Amann M, Wuerfel J., Collins D.L., Gaetano L., Magon S., Sprenger T, Kappos L., Granziera C., & Tsagkas C. (2022). Regional Cerebellar Volume Loss Predicts Future Disability in Multiple Sclerosis Patients. Cerebellum (London, England), 21(4), 632–646. https://doi.org/10.1007/s12311-021-01312-0

URLs
URLs

Sharmin S, Bovis F, Malpas C, Horakova D, Havrdova EK, Izquierdo G, Eichau S, Trojano M, Prat A, Girard M, Duquette P, Onofrj M, Lugaresi A, Grand’Maison F, Grammond P, Sola P, Ferraro D, Terzi M, Gerlach O, et al. (2022). Confirmed disability progression as a marker of permanent disability in multiple sclerosis. European Journal of Neurology, 29(8), 2321–2334. https://doi.org/10.1111/ene.15406

URLs
URLs

Tur C, Dubessy AL, Otero-Romero S, Amato MP, Derfuss T, Di Pauli F, Iacobaeus E, Mycko M, Abboud H, Achiron A, Bellinvia A, Boyko A, Casanova JL, Clifford D, Dobson R, Farez MF, Filippi M, Fitzgerald KC, Fonderico M, et al. (2022). The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Multiple Sclerosis (Houndmills, Basingstoke, England), 28(9), 1424–1456. https://doi.org/10.1177/13524585211069068

URLs
URLs

Battaglini M, Vrenken H, Tappa Brocci R, Gentile G, Luchetti L, Versteeg A, Freedman MS, Uitdehaag BMJ, Kappos L, Comi G, Seitzinger A, Jack D, Sormani MP, Barkhof F, & De Stefano N. (2022). Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta-1a. European Journal of Neurology, 29(7), 2024–2035. https://doi.org/10.1111/ene.15314

URLs
URLs

Manuel Escobar J, Cortese M, Edan G, Freedman MS, Hartung HP, Montalbán X, Sandbrink R, Radü EW, Barkhof F, Wicklein EM, Kappos L, Ascherio A, & Munger KL. (2022). Body mass index as a predictor of MS activity and progression among participants in BENEFIT. Multiple Sclerosis (Houndmills, Basingstoke, England), 28(8), 1277–1285. https://doi.org/10.1177/13524585211061861

URLs
URLs

Leppert D, Kropshofer H, Häring DA, Dahlke F, Patil A, Meinert R, Tomic D, Kappos L, & Kuhle J. (2022). Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials. Neurology, 98(21), e2120–e2131. https://doi.org/10.1212/wnl.0000000000200258

URLs
URLs

Müller J, Sinnecker T, Wendebourg MJ, Schläger R, Kuhle J, Schädelin S, Benkert P, Derfuss T, Cattin P, Jud C, Spiess F, Amann M, Lincke T, Barakovic M, Cagol A, Tsagkas C, Parmar K, Pröbstel AK, Reimann S, et al. (2022). Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder: A Retrospective, Cross-sectional Analysis. Neurology(R) Neuroimmunology & Neuroinflammation, 9(3). https://doi.org/10.1212/nxi.0000000000001147

URLs
URLs

Wendebourg MJ, Weigel M, Richter L, Gocheva V, Hafner P, Orsini A.-L., Crepulja V, Schmidt S, Huck A., Oechtering J., Blatow M, Haas T., Granziera C, Kappos L, Cattin P, Bieri O., Fischer D, & Schlaeger R. (2022). Spinal cord gray matter atrophy is associated with functional decline in post-polio syndrome. European Journal of Neurology, 29(5), 1435–1445. https://doi.org/10.1111/ene.15261

URLs
URLs

Butzkueven H., Spelman T., Horakova D., Hughes S., Solaro C., Izquierdo G., Kubala Havrdova E., Grand’Maison F., Prat A., Girard M., Hupperts R., Onofrj M., Lugaresi A., Taylor B., Giovannoni G., Kappos L., Hauser S.L., Montalban X., Craveiro L., et al. (2022). Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry. European Journal of Neurology, 29(4), 1082–1090. https://doi.org/10.1111/ene.14824

URLs
URLs

Giovannoni G., Kappos L., de Seze J., Hauser S.L., Overell J., Koendgen H., Manfrini M., Wang Q., & Wolinsky J.S. (2022). Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials. European Journal of Neurology, 29(4), 1238–1242. https://doi.org/10.1111/ene.14823

URLs
URLs

Gold R., Arnold D.L., Bar-Or A., Fox R.J., Kappos L., Mokliatchouk O., Jiang X., Lyons J., Kapadia S., & Miller C. (2022). Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results. Multiple Sclerosis Journal, 28(5), 801–816. https://doi.org/10.1177/13524585211037909

URLs
URLs

Kuhle J, Daizadeh N, Benkert P, Maceski A, Barro C, Michalak Z, Sormani MP, Godin J, Shankara S, Samad TA, Jacobs A, Chung L, Rӧsch N, Kaiser C, Mitchell CP, Leppert D, Havari E, & Kappos L. (2022). Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS. Multiple Sclerosis (Houndmills, Basingstoke, England), 28(4), 573–582. https://doi.org/10.1177/13524585211032348

URLs
URLs

Malpas CB, Roos I, Sharmin S, Buzzard K, Skibina O, Butzkueven H, Kappos L, Patti F, Alroughani R, Horakova D, Havrdova EK, Izquierdo G, Eichau S, Hodgkinson S, Grammond P, Lechner-Scott J, Kalincik T, & MSBase Study Group. (2022). Multiple Sclerosis Relapses Following Cessation of Fingolimod. Clinical Drug Investigation, 42(4), 355–364. https://doi.org/10.1007/s40261-022-01129-7

URLs
URLs

Schiavi S, Lu PJ, Weigel M, Lutti A, Jones DK, Kappos L, Granziera C, & Daducci A. (2022). Bundle myelin fraction (BMF) mapping of different white matter connections using microstructure informed tractography. NeuroImage, 249, 118922. https://doi.org/10.1016/j.neuroimage.2022.118922

URLs
URLs

Zandl-Lang M, Züllig T, Trötzmüller M, Naegelin Y, Abela L, Wilken B, Scholl-Buergi S, Karall D, Kappos L, Köfeler H, & Plecko B. (2022). Changes in the Cerebrospinal Fluid and Plasma Lipidome in Patients with Rett Syndrome. Metabolites, 12(4). https://doi.org/10.3390/metabo12040291

URLs
URLs

Kropshofer H, Häring DA, Kappos L, Leppert D, & Kuhle J. (2022). Reader Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis. (Patent No. 11). 98(11), Article 11. https://doi.org/10.1212/wnl.0000000000200132

URLs
URLs

Bosticardo S, Schiavi S, Schaedelin S, Lu PJ, Barakovic M, Weigel M, Kappos L, Kuhle J, Daducci A, & Granziera C. (2022). Microstructure-Weighted Connectomics in Multiple Sclerosis. Brain Connectivity, 12(1), 6–17. https://doi.org/10.1089/brain.2021.0047

URLs
URLs

Cagol, Alessandro, Schaedelin, Sabine, Barakovic, Muhamed, Benkert, Pascal, Todea, Ramona-Alexandra, Rahmanzadeh, Reza, Galbusera, Riccardo, Lu, Po-Jui, Weigel, Matthias, Melie-Garcia, Lester, Ruberte, Esther, Siebenborn, Nina, Battaglini, Marco, Radue, Ernst-Wilhelm, Yaldizli, Özgür, Oechtering, Johanna, Sinnecker, Tim, Lorscheider, Johannes, Fischer-Barnicol, Bettina, et al. (2022). Association of Brain Atrophy with Disease Progression Independent of Relapse Activity in Patients with Relapsing Multiple Sclerosis. JAMA Neurology, 79, 682–692. https://doi.org/10.1001/jamaneurol.2022.1025

URLs
URLs

De Brouwer E, Becker T, Moreau Y, Havrdova EK, Trojano M, Eichau S, Ozakbas S, Onofrj M, Grammond P, Kuhle J, Kappos L, Sola P, Cartechini E, Lechner-Scott J, Alroughani R, Gerlach O, Kalincik T, Granella F, Grand’Maison F, et al. (2022). Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180]. 213, 106479. https://doi.org/10.1016/j.cmpb.2021.106479

URLs
URLs

Diebold, Martin, Galli, Edoardo, Kopf, Andreas, Sanderson, Nicholas, Callegari, Ilaria, Ingelfinger, Florian, Núñez, Nicolás Gonzalo, Benkert, Pascal, Kappos, Ludwig, Kuhle, Jens, Becher, Burkhard, Claassen, Manfred, & Derfuss, Tobias. (2022). Immunological Predictors of Dimethyl Fumarate-Induced Lymphopenia. Annals of Neurology, 91, 676–681. https://doi.org/10.1002/ana.26328

URLs
URLs

Diebold, Martin, Galli, Edoardo, Kopf, Andreas, Sanderson, Nicholas S.R., Callegari, Ilaria, Benkert, Pascal, Nuñez, Nicolas Gonzalo, Ingelfinger, Florian, Herms, Stefan, Cichon, Sven, Kappos, Ludwig, Kuhle, Jens, Becher, Burkhard, Claassen, Manfred, & Derfuss, Tobias. (2022). High-dimensional immune profiling identifies a biomarker to monitor dimethyl fumarate response in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 119. https://doi.org/10.1073/pnas.2205042119

URLs
URLs

Diebold, Martin, Meola, Marco, Purushothaman, Srinithi, Siewert, Lena K, Pössnecker, Elisabeth, Roloff, Tim, Lindberg, Raija LP, Kuhle, Jens, Kappos, Ludwig, Derfuss, Tobias, Egli, Adrian, & Pröbstel, Anne-Katrin. (2022). Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosis. Gut Microbes, 14. https://doi.org/10.1080/19490976.2022.2147055

URLs
URLs

Hardmeier, M., Hardmeier, M., Schlaeger, R., Lascano, A. M., Toffolet, L., Schindler, C., Gobbi, C., Lalive, P., Kuhle, J., Kappos, L., & Fuhr, P. (2022). Prognostic biomarkers in primary progressive multiple sclerosis: validating and scrutinizing multimodal evoked potentials. Clinical neurophysiology, 137, 152–158. https://doi.org/10.1016/j.clinph.2022.02.019

URLs
URLs

Lokhande H, Rosso M., Tauhid S, Chu R, Healy BC, Saxena S, Barro C, Paul A, Polgar-Turcsanyi M, Anderson M., Glanz BI, Kropshofer H, Granziera C, Leppert D, Kappos L, Kuhle J., Weiner HL, Bakshi R., & Chitnis T. (2022). Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 8(1). https://doi.org/10.1177/20552173211069348

URLs
URLs

Mattiesing RM, Gentile G, Brouwer I, van Schijndel RA, Uitdehaag BMJ, Twisk JWR, Kappos L, Freedman MS, Comi G, Jack D, De Stefano N, Barkhof F, Battaglini M, & Vrenken H. (2022). The spatio-temporal relationship between white matter lesion volume changes and brain atrophy in clinically isolated syndrome and early multiple sclerosis. NeuroImage. Clinical, 36, 103220. https://doi.org/10.1016/j.nicl.2022.103220

URLs
URLs